Matthew Todd (chemist)

Last updated

Matthew H. Todd
Matthew H. Todd.jpg
Born
Matthew Houghton Todd

(1973-01-13) 13 January 1973 (age 51)
Manchester, United Kingdom
Alma mater University of Cambridge
Known for Open Source Malaria
Open Source Tuberculosis
Open Source Mycetoma
Scientific career
Fields
Institutions
Thesis Novel encoding strategies for combinatorial chemistry  (1998)
Doctoral advisor Chris Abell
Other academic advisorsPaul A. Bartlett
Notable students Alice Motion
Website The Todd Group

Matthew Houghton Todd (born 13 January 1973) is a British chemist and the Professor and Chair of Drug Discovery of the School of Pharmacy at University College London. [1] He is the founder of Open Source Malaria (OSM) and his research focuses on drug discovery and development for this disease. [2] [3] [4] [5] [6] Recently, he has expanded to other areas, particularly neglected diseases such as tuberculosis and mycetoma [7] in the Open Source Tuberculosis (OSTB) and Open Source Mycetoma (MycetOS) project, through a collaboration with the Drugs for Neglected Diseases Initiative and Erasmus MC. [8] In addition, he has some research activity in catalysis and methodology. [9] [10] [11] [12]

Contents

Education

Todd received an MA in Natural Sciences from the University of Cambridge in 1995. He obtained his PhD in Organic Chemistry at the same institution in 1999, working with Chris Abell on encoding and linker strategies for combinatorial chemistry. [13] [14] [15] [16] Todd was a Wellcome Trust Postdoctoral Research Fellow at the University of California, Berkeley from 1999 to 2000, working with Paul A. Bartlett on synthesis of amino acid-derived heterocycles by Lewis acid catalysis and radical cyclisations from peptide acetals. [17] [18]

Career and research

From 2000 to 2001, he was a College Fellow and Lecturer at New Hall, Cambridge (now Murray Edwards College, Cambridge). He began his independent research career in 2001 at Queen Mary University of London. In 2005, he relocated to Australia where he was a lecturer, senior lecturer, then associate professor at the School of Chemistry, University of Sydney. In 2018, he returned to the United Kingdom to take the role of professor and Chair of Drug Discovery at UCL School of Pharmacy. [1]

In response to the price hike of HIV/AIDS drug, pyrimethamine (Daraprim), by Turing Pharmaceuticals, [19] Todd and the Open Source Malaria team led a small team of high school students from Sydney Grammar School to synthesise the drug. [20] [21] The students produced 3.7 grams of pyrimethamine for US$20, which would be worth between US$35,000 and US$110,000 in the United States based on hiked prices. [22] This received significant media attention and was featured on ABC, [22] BBC, [23] CNN, [24] The Guardian, [21] and Time. [25]

Todd has been a vocal proponent of open science and open research. [2] [5] [26] [27] [28] [29] In 2011, he proposed Six Laws of Open Research to guide present and future open research projects including OSM and MycetOS: [5] [30] [31] [32] [33]

  1. All data are open and all ideas are shared.
  2. Anyone can take part at any level of the project.
  3. There will be no patents.
  4. Suggestions are the best form of criticism.
  5. Public discussion is much more valuable than private email.
  6. The project is bigger than, and is not owned by, any given lab. The aim is to find a good drug for malaria, by whatever means, as quickly as possible.

Todd is on the Editorial boards of Chemistry Central Journal, [34] ChemistryOpen, [35] PLOS One, [36] Scientific Reports, [37] and Scientific Data. [38]

Honours and awards

See also

Related Research Articles

<span class="mw-page-title-main">Robert Koch</span> German physician and bacteriologist (1843–1910)

Heinrich Hermann Robert Koch was a German physician and microbiologist. As the discoverer of the specific causative agents of deadly infectious diseases including tuberculosis, cholera and anthrax, he is regarded as one of the main founders of modern bacteriology. As such he is popularly nicknamed the father of microbiology, and as the father of medical bacteriology. His discovery of the anthrax bacterium in 1876 is considered as the birth of modern bacteriology. Koch used his discoveries to establish that germs "could cause a specific disease" and directly provided proofs for the germ theory of diseases, therefore creating the scientific basis of public health, saving millions of lives. For his life's work Koch is seen as one of the founders of modern medicine.

Tropical diseases are diseases that are prevalent in or unique to tropical and subtropical regions. The diseases are less prevalent in temperate climates, due in part to the occurrence of a cold season, which controls the insect population by forcing hibernation. However, many were present in northern Europe and northern America in the 17th and 18th centuries before modern understanding of disease causation. The initial impetus for tropical medicine was to protect the health of colonial settlers, notably in India under the British Raj. Insects such as mosquitoes and flies are by far the most common disease carrier, or vector. These insects may carry a parasite, bacterium or virus that is infectious to humans and animals. Most often disease is transmitted by an insect bite, which causes transmission of the infectious agent through subcutaneous blood exchange. Vaccines are not available for most of the diseases listed here, and many do not have cures.

<span class="mw-page-title-main">Tropical medicine</span> Interdisciplinary branch of medicine

Tropical medicine is an interdisciplinary branch of medicine that deals with health issues that occur uniquely, are more widespread, or are more difficult to control in tropical and subtropical regions.

<span class="mw-page-title-main">Eumycetoma</span> Human and animal fungal infection

Eumycetoma, also known as Madura foot, is a persistent fungal infection of the skin and the tissues just under the skin, affecting most commonly the feet, although it can occur in hands and other body parts. It starts as a painless wet nodule, which may be present for years before ulceration, swelling, grainy discharge and weeping from sinuses and fistulae, followed by bone deformity.

Since October 2018, the Center for Global Infectious Disease Research has been part of the Seattle Children's Research Institute. At the time of the merger, CID Research had 166 scientists. Its mission was to eliminate the world's most devastating infectious diseases through leadership in scientific discovery. The organization's research labs were in the South Lake Union area of Seattle, WA. The institute's research focused on four areas of infectious disease: HIV/AIDS, malaria, tuberculosis (TB), and Emerging & Neglected Diseases (END) like African sleeping sickness, leishmaniasis, Chagas disease, and toxoplasmosis. CID Research was engaged in early stages of the scientific pipeline including bench science and malaria clinical trials and has expertise in immunology, vaccinology, and drug discovery.

<span class="mw-page-title-main">Open research</span> Research made available to the public

Open research is research that is openly accessible by others. Those who publish research in this way are often concerned with making research more transparent, more collaborative, more wide-reaching, and more efficient. Open research aims to make both research methods and the resulting data freely available, often via the internet, in order to support reproducibility and, potentially, massively distributed research collaboration. In this regard, it is related to both open source software and citizen science.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Neglected tropical diseases</span> Diverse group of tropical infectious diseases which are common in developing countries

Neglected tropical diseases (NTDs) are a diverse group of tropical infections that are common in low-income populations in developing regions of Africa, Asia, and the Americas. They are caused by a variety of pathogens, such as viruses, bacteria, protozoa, and parasitic worms (helminths). These diseases are contrasted with the "big three" infectious diseases, which generally receive greater treatment and research funding. In sub-Saharan Africa, the effect of neglected tropical diseases as a group is comparable to that of malaria and tuberculosis. NTD co-infection can also make HIV/AIDS and tuberculosis more deadly.

Mycetoma is a chronic infection in the skin caused by either bacteria (actinomycetoma) or fungi (eumycetoma), typically resulting in a triad of painless firm skin lumps, the formation of weeping sinuses, and a discharge that contains grains. 80% occur in feet.

Samir Kumar Brahmachari is an Indian biophysicist and Former Director General of the Council of Scientific & Industrial Research (CSIR) and Former Secretary, Department of Scientific and Industrial Research (DSIR), Government of India. He is the Founder Director of Institute of Genomics and Integrative Biology (IGIB), New Delhi and the Chief Mentor of Open Source for Drug Discovery (OSDD) Project. He is the recipient of J.C Bose Fellowship Award, DST (2012). In addition, he is one of the featured researchers in the India Cancer Research Database developed by Institute of Bioinformatics (IOB), Bangalore with support from the Department of Biotechnology, Government of India.

<span class="mw-page-title-main">Collaborative Drug Discovery</span>

Collaborative Drug Discovery (CDD) is a software company founded in 2004 as a spin-out of Eli Lilly by Barry Bunin, PhD. CDD utilizes a web-based database solution for managing drug discovery data, primarily through the CDD Vault product which is focused around small molecules and associated bio-assay data. In 2021, CDD launched its first commercial data offering, PharmaKB, formerly BioHarmony, as The Pharma KnowledgeBase, which is centered around pharma company, drug, and disease information for research, business intelligence, and investors.

<span class="mw-page-title-main">ChEMBL</span> Chemical database of bioactive molecules also having drug-like properties

ChEMBL or ChEMBLdb is a manually curated chemical database of bioactive molecules with drug inducing properties. It is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based at the Wellcome Trust Genome Campus, Hinxton, UK.

<span class="mw-page-title-main">Sean Ekins</span>

Sean Ekins is a British pharmacologist and expert in the fields of ADME/Tox, computational toxicology and cheminformatics at Collaborations in Chemistry, a division of corporate communications firm Collaborations in Communications. He is also the editor of four books and a book series for John Wiley & Sons.

<span class="mw-page-title-main">Fenarimol</span> Chemical compound

Fenarimol, sold under the tradenames Bloc, Rimidin and Rubigan, is a fungicide which acts against rusts, blackspot and mildew fungi. It is used on ornamental plants, trees, lawns, tomatoes, peppers, eggplants, cucumbers and melons. It is mainly used to control powdery mildew. It works by inhibiting the fungus's biosynthesis of important steroid molecules.

Open Source Drug Discovery is a Council of Scientific and Industrial Research, India (CSIR)-led Team India Consortium with global participation offering a collaborative drug discovery platform for neglected tropical diseases like leishmaniasis, which draw limited attention of research-based pharmaceutical enterprises. This program has a global community with over 7500 participants from 130 countries comprising researchers, academia, students, industries, educational institutions and so on. Anyone who is committed to the discovery of drugs for neglected diseases in an open source mode can participate in the program. OSDD functions by bringing together experts from diverse backgrounds to focus on discovering and developing affordable drugs for tropical infections.

Kelly Chibale PhD, MASSAf, FAAS, Fellow of UCT, FRSSAf, FRSC is professor of organic chemistry at the University of Cape Town, and the founder and director of H3D research center and H3D Foundation NPC. In 2018 he was recognised as one of Fortune magazine's top 50 World's Greatest Leaders. His research focuses on drug discovery and the development of tools and models to contribute to improving treatment outcomes in people of African descent or heritage.

<span class="mw-page-title-main">Alice Motion</span> British chemist and science communicator (born 1984)

Alice Elizabeth Motion is a British chemist, science communicator, and associate professor at the School of Chemistry, University of Sydney. She is the founder of the Breaking Good project which encourages high school and undergraduate students to take part in research that can benefit human health. In 2018, the Breaking Good project was a finalist on the Google.org Impact Challenge.

Neglected tropical diseases in India are a group of bacterial, parasitic, viral, and fungal infections that are common in low income countries but receive little funding to address them. Neglected tropical diseases are common in India.

<span class="mw-page-title-main">David Molyneux</span> British parasitologist

David Hurst Molyneux CMG is a British parasitologist who served as the Director of the Liverpool School of Tropical Medicine (1991–2000), where, as of 2018, he is an emeritus professor. He previously held the Chair of Biological Sciences at the University of Salford (1977–91), where he also served as Dean of the Faculty of Science. His research and advocacy have focused on what are now known as neglected tropical diseases, and Michael Barrett credits him as among the earliest advocates of the campaign to focus international attention on this group of diseases in the early-to-mid 2000s.

Lyda Elena Osorio Amaya is a Colombian physician, epidemiologist and infectious disease specialist. She is an associate professor at the Universidad del Valle, and a researcher at the Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM) in Cali, Valle del Cauca. Osorio's research has focused mainly on vector-borne diseases like malaria, leishmaniasis, Zika and dengue fever. She has also played a role in Colombia's response against COVID-19.

References

  1. 1 2 "Professor Matthew Todd – UCL School of Pharmacy". 2 October 2018.
  2. 1 2 Peplow, M (2019). "Open-source drug discovery takes aim at malaria and neglected diseases". C&EN. ACS. Retrieved 13 February 2019.
  3. ↑ Lowe, D. "The Open Source Malaria Project, So Far". In The Pipeline. Retrieved 13 February 2019.
  4. ↑ Williamson, AE (2016). "Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles". ACS Central Science. 2 (10): 687–701. doi:10.1021/acscentsci.6b00086. PMC   5084075 . PMID   27800551.
  5. 1 2 3 Robertson, MN (2014). "Open source drug discovery – A limited tutorial". Parasitology. 141 (1): 148–157. doi:10.1017/S0031182013001121. PMC   3884843 . PMID   23985301.
  6. ↑ Tse, EG; Korsik, M; Todd, MH (2019). "The past, present and future of anti-malarial medicines". Malaria Journal. 18 (1): 93. doi: 10.1186/s12936-019-2724-z . PMC   6431062 . PMID   30902052.
  7. ↑ Lim, W (2018). "Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma". PLOS Neglected Tropical Diseases. 12 (2): e0006437. doi: 10.1371/journal.pntd.0006437 . PMC   5940239 . PMID   29698504.
  8. ↑ "MycetOS – DNDi". 31 December 2017.
  9. ↑ Park, SJ (2002). "Oxidative Arylation of Isochroman". Journal of Organic Chemistry. 77 (2): 949–955. doi:10.1021/jo2021373. PMID   22142205.
  10. ↑ Tsang, ASK (2009). "Facile synthesis of vicinal diamines via oxidation of N-phenyltetrahydroisoquinolines with DDQ". Tetrahedron Letters. 50 (11): 1199–1202. doi:10.1016/j.tetlet.2008.12.101.
  11. ↑ Hashmi, ASK (2010). "Gold-Catalysis: Reactions of Organogold Compounds with Electrophiles". Australian Journal of Chemistry. 63 (12): 1619–1626. doi:10.1071/CH10342.
  12. ↑ Ahamed, M (2010). "Catalytic Asymmetric Additions of Carbon-Centered Nucleophiles to Nitrogen-Containing Aromatic Heterocycles". European Journal of Organic Chemistry. 2010 (31): 5935–5942. doi:10.1002/ejoc.201000877.
  13. ↑ Todd, MH (1997). "Studies on the synthesis, characterisation and reactivity of aromatic diboronic acids". Tetrahedron Letters. 38 (38): 6781–6784. doi:10.1016/S0040-4039(97)01552-9.
  14. ↑ Todd, MH (2001). "Novel chemical tagging method for combinatorial synthesis utilizing Suzuki chemistry and Fourier transform ion cyclotron resonance mass spectrometry". Journal of Combinatorial Chemistry. 3 (3): 319–327. doi:10.1021/cc000112m. PMID   11350256.
  15. ↑ Todd, MH (1999). "A novel safety-catch linker for the solid-phase synthesis of amides and esters". Organic Letters. 1 (8): 1149–1151. doi:10.1021/ol990785h.
  16. ↑ "Past Members - The Abell Group" . Retrieved 12 February 2019.
  17. ↑ Todd, MH (2002). "Amino acid derived heterocycles: Lewis acid catalyzed and radical cyclizations from peptide acetals". Journal of Organic Chemistry. 67 (12): 3985–3988. doi:10.1021/jo010990m. PMID   12054930.
  18. ↑ "Paul A. Bartlett Group Alumni" . Retrieved 12 February 2019.
  19. ↑ Timmerman, L. "A Timeline of the Turing Pharma Controversy". Forbes. Retrieved 12 February 2019.
  20. ↑ Reiner, V (30 November 2016). "Students make $750 drug cheaply with Open Source Malaria team". University of Sydney. Retrieved 13 February 2019.
  21. 1 2 Davey, M. "Australian students recreate Martin Shkreli price-hike drug in school lab". The Guardian. Retrieved 12 February 2019.
  22. 1 2 Hunjan, R. "Daraprim drug's key ingredient recreated by high school students in Sydney for just $20". ABC. Retrieved 12 February 2019.
  23. ↑ Dunlop, G. "Martin Shkreli: Australian boys recreate life-saving drug". BBC. Retrieved 12 February 2019.
  24. ↑ Roberts, E. "'Pharma Bro' Martin Shkreli meets his match in a group of Australian schoolboys". CNN. Retrieved 12 February 2019.
  25. ↑ Lui, K. "Watch Martin Shkreli Respond to the School Kids Who Recreated His Drug for $2 a Dose". Time.
  26. ↑ Woelfle, M (2011). "Open science is a research accelerator". Nature Chemistry. 3 (10): 745–748. Bibcode:2011NatCh...3..745W. doi: 10.1038/nchem.1149 . PMID   21941234. S2CID   205289283.
  27. ↑ Laursen, L (2016). "Tropical disease: A neglected cause". Nature. 533 (7602): S68–S69. Bibcode:2016Natur.533S..68L. doi: 10.1038/533S68a . PMID   27167396.
  28. ↑ Anderson, T (2016). "Can open-source drug development deliver?". The Lancet. 387 (10032): 1983–1984. doi:10.1016/S0140-6736(16)30518-9. PMID   27203757. S2CID   44792421.
  29. ↑ Todd, MH. "Why open source pharma is the path to both new and cheaper medicines". The Guardian. Retrieved 12 February 2019.
  30. ↑ Todd, MH. "Open Source Drug Discovery for Malaria" . Retrieved 12 February 2019.
  31. ↑ Pearce, R. "Researchers look to open source to tackle deadly infection" . Retrieved 12 February 2019.
  32. ↑ "Open Source Research – OpenWetWare" . Retrieved 12 February 2019.
  33. ↑ Williamson, AE. "Open science: the future of research?". ABC. Retrieved 12 February 2019.
  34. ↑ "Chemistry Central Journal (Editorial Board)". Chemistry Central Journal. Retrieved 12 February 2019.
  35. ↑ "Editorial Advisory Board". ChemistryOpen. Retrieved 12 February 2019.
  36. ↑ "Editorial Board". PLOS ONE. Retrieved 12 February 2019.
  37. ↑ "Editorial Advisory Panel and Editorial Board". Scientific Reports. Retrieved 12 February 2019.
  38. ↑ "Editors, Advisory Panel & Editorial Board". Scientific Data. Retrieved 12 February 2019.
  39. ↑ "Honour Roll – NSW Chief Scientist & Engineer". NSW Chief Scientist & Engineer. Archived from the original on 14 August 2020. Retrieved 15 October 2021.
  40. ↑ "ANNOUNCING THE RECIPIENTS FOR THE ACCELERATING SCIENCE AWARD PROGRAM". The Official PLOS Blog. 21 October 2013.
  41. ↑ "Blue Obelisk Awards". blueobelisk.github.io. Retrieved 27 April 2019.
  42. ↑ "The Power List 2017". The Medicine Maker. 9 August 2023.
  43. ↑ "The Power List 2018". The Medicine Maker. 9 August 2023.
  44. ↑ "The Power List 2019". The Medicine Maker. 9 August 2023.
  45. ↑ "The Power List 2020". The Medicine Maker. 9 August 2023.
  46. ↑ "The Power List 2021". The Medicine Maker. 9 August 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.